other glp 1 receptor agonists GLP-1 GLP-1 Receptor Agonists as Treatments
Description
FAERS is a passive surveillance database and is subject to underreporting, reporting bias, and incomplete clinical detail
Cell Metab 3:153165 Nauck MA, Quast DR, Wefers J, Pfeiffer AFH (2021) The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update
Adverse Effects of GLP-1 Receptor Agonists
A four-week hold is roughly the window needed for a step to reach steady state and for the gut to adapt to it, which is why escalating before the block is complete effectively means judging a dose you have not yet fully experienced
Am J Clin Nutr 95: 7883
The slowed movement through your digestive system can affect bowel patterns, though the specific effects vary considerably between individuals
